Logout
If you want to log out click in LogOut
The IL6 STAT3 signaling pathway is a cytokine-driven signaling cascade that plays a central role in inflammation, immune regulation, cell survival, and proliferation. It is activated when interleukin-6 (IL-6) binds to its receptor complex, leading to JAK-mediated phosphorylation of STAT3 and transcriptional regulation of downstream target genes.
This pathway is essential for normal immune responses and tissue repair. However, persistent activation of IL6 STAT3 signaling is strongly associated with chronic inflammatory diseases, cancer progression, immune evasion, and resistance to therapy.
IL6 STAT3 pathway activity can be efficiently assessed by measuring gene expression of pathway regulators and STAT3-dependent biomarkers.
IL6 STAT3 signaling biomarker list
View the genes included in our IL6 STAT3 qPCR arrays.
A pleiotropic cytokine involved in immune activation, acute-phase responses, and tissue regeneration. Dysregulated IL-6 production sustains chronic inflammation and tumor-promoting environments.
JAK1, JAK2, and TYK2 phosphorylate STAT3 following IL-6 receptor engagement.
A transcription factor that controls genes involved in survival, proliferation, angiogenesis, immune suppression, and metastasis.
SOCS proteins and phosphatases limit signal duration and intensity.
IL6 STAT3 signaling interacts with PI3K/AKT, NF-κB, MAPK, and mTOR pathways, amplifying disease-relevant responses.
The IL6 STAT3 pathway regulates:
Cancer
Autoimmune and inflammatory diseases
Chronic IL6 STAT3 signaling contributes to:
Metabolic and cardiovascular diseases
STAT3-driven inflammation is linked to insulin resistance, obesity, and vascular dysfunction.
The IL6 STAT3 pathway is a major therapeutic target:
Gene expression–based biomarker analysis is essential for patient stratification and treatment monitoring.
At AnyGenes®, we provide high-performance qPCR arrays and customizable SignArrays® designed for IL6 STAT3 pathway analysis.
Our solutions enable researchers to:
What can be analyzed?
Scientific data is only as powerful as the analysis behind it.
AnyGenes® provides a dedicated data analysis tool specifically developed for SignArrays® pathway panels.
What does it allow you to do?
Developed on Excel (compatible with 2007+), the software is user-friendly and requires no advanced bioinformatics skills.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
[email protected]
to initiate your project.
It is a cytokine-driven pathway linking IL-6 receptor activation to STAT3-dependent gene transcription involved in inflammation, immunity, and cancer.
Persistent STAT3 activation promotes tumor growth, angiogenesis, immune evasion, and therapy resistance.
Key genes include IL6, IL6R, JAK1/2, STAT3, SOCS3, and STAT3 downstream targets.
By measuring expression of pathway regulators and downstream genes using targeted qPCR pathway arrays.
| Signaling Pathways | Product ref | Informations |
|---|---|---|
IL6-STAT3 Signaling Pathway | IL61H1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
IL6-STAT3 Signaling Pathway | IL61M1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
IL6-STAT3 Signaling Pathway | ******* |
Biomarker list in progress. |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
IL6-STAT3 Signaling Pathway | ******* |
Biomarker list in progress. |
Looking for more answers? Visit our Help & FAQ section to find detailed informations about our products, services, and technical support.
1. Kang S, et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. (2019) 16;50(4):1007-1023.
2. Song Z, et al. Molecular cross-talk of IL-6 in tumors and new progress in combined therapy. Thorac Cancer. (2018);9(6):669-675.
3. Galoczova M, et al. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. (2018)22;23:12.
4. Johnson DE, et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. (2018);15(4):234-248.
5. Yan Lin et al. Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer. Onco Targets Ther. (2020)21;13:13023-13032.
6. Moshapa FT, et al. Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus. Cardiol Res Pract. (2019)2;2019:9846312.
7. Liu Y, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. (2021);54(2):e12974.
8. Kasembeli MM, et al. Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci. (2018)5;19(8):2299.
9. Mohrherr J, et al. STAT3: Versatile Functions in Non-Small Cell Lung Cancer. Cancers (Basel). (2020)29;12(5):1107.